SOURCE: China Aoxing Pharmaceutical Co., Inc.

April 28, 2009 08:00 ET

China Aoxing Pharmaceutical Company to Present at the Eighth Annual JMP Securities Research Conference in San Francisco on May 20, 2009

NEW YORK, NY--(Marketwire - April 28, 2009) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing" or the "Company"), a pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will present at the Eighth Annual JMP Securities Research Conference at the Ritz-Carlton, San Francisco on May 20, 2009.

The presentation will take place between 10:30 to 11:00 AM PDT. The Company will update the Company business including product portfolio, development pipeline, financial highlights and its long-term growth strategies. The management will participate in meetings with analysts and investors throughout the day.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

  • Contact:

    Wei Zhang
    Investor Relations
    China Aoxing Pharmaceutical Company, Inc
    Email: chinaaoxing@gmail.com
    Telephone: 646 - 512 - 5662